GLP-1
Novo Nordiskās Wegovy boosts heart health, J.P. Morgan predicts $71B GLP-1 market by 2032
Anika Sharma
The demand for Novo Nordisk’s obesity medications is surging, with production capacity being the primary limiting factor in the short ...
Novo Nordisk and Eli Lilly Drive Breakthroughs in Oral GLP-1 Treatments for Obesity at ADA Conference
SG Tylor
Novo Nordisk and Eli Lilly showcased advancements in the development of oral GLP-1 treatments for Type II diabetes and obesity ...
Pfizer Shares Progress of Clinical Development Program for GLP-1-RA in Adults with Obesity and Type II Diabetes Mellitus
SG Tylor
Source – Pfizer On June 26, 2023, Pfizer Provides Update on Clinical Development Program for GLP-1-RA in Obesity and Type ...
Lilly’s Orforglipron Shows Promising Weight Reduction in Obesity and Overweight Patients: Phase II Findings
SG Tylor
Source – Eli Lilly On June 23, 2023, Eli Lilly and Company announced the Phase II results for orforglipron, an ...
EU Drug Regulator Scrutinizes Novo Nordisk and Eli Lilly Over GLP-1 Safety
SG Tylor
The increased inspection of GLP-I therapies by the European Medicines Agency (EMA) has raised a warning about the possibility that ...
